Glaukos Co. (NYSE:GKOS) Stock Holdings Increased by Schroder Investment Management Group

Schroder Investment Management Group boosted its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 213.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 10,259 shares of the medical instruments supplier's stock after buying an additional 6,991 shares during the period. Schroder Investment Management Group's holdings in Glaukos were worth $1,538,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. IFP Advisors Inc acquired a new position in shares of Glaukos during the fourth quarter worth about $43,000. Asset Planning Inc acquired a new position in Glaukos during the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management purchased a new position in Glaukos in the 4th quarter worth approximately $125,000. SBI Securities Co. Ltd. purchased a new position in Glaukos in the 4th quarter worth approximately $153,000. Finally, Smartleaf Asset Management LLC grew its position in Glaukos by 275.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after acquiring an additional 807 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Piper Sandler reissued an "overweight" rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Needham & Company LLC lifted their target price on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Truist Financial reduced their price target on Glaukos from $185.00 to $140.00 and set a "buy" rating for the company in a report on Friday. Finally, Stifel Nicolaus lifted their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $159.50.

Glaukos Stock Performance

GKOS traded up $0.39 during trading hours on Friday, hitting $90.05. 533,122 shares of the stock were exchanged, compared to its average volume of 629,798. The stock has a market cap of $5.09 billion, a price-to-earnings ratio of -31.38 and a beta of 0.88. The stock has a 50-day simple moving average of $114.19 and a 200-day simple moving average of $132.66. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 12 month low of $77.91 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.